Acute Kidney Injury Causes and Management

Nephrotoxic Agents Including Drugs

• Nephrotoxic drugs are a well-established cause of intrarenal acute kidney injury, characterized by glomerular or tubular cell injury triggered by filtered toxins, tubular obstruction, endothelial dysfunction, or allergic reactions 1
• Drugs account for approximately 20% of community-acquired AKI episodes resulting in hospitalization and occur in about 25% of critically ill patients 2
• NSAIDs can cause AKI through altered intraglomerular hemodynamics and are part of the dangerous "triple whammy" combination with diuretics and ACE inhibitors/ARBs 2
• The consequences of drug-associated AKI are severe, with rates of dialysis dependence and mortality similar to those of AKI from other etiologies (40-50%) 2

Decreased Renal Perfusion

• Kidney dysfunction can result from systemic hypotension or altered intraglomerular hemodynamics, leading to decreased renal perfusion pressure 3
• If decreased renal perfusion is sustained or severe, it can lead to ischemic injury of the kidney 3
• Renal hypoperfusion can be caused by true volume depletion or effective circulatory volume depletion, such as heart failure or cirrhosis 4
• In patients with cirrhosis, decreased renal perfusion is a common cause of AKI, with fractional excretion of sodium typically <1% 4
• Early reversal of AKI from decreased renal perfusion leads to improved survival compared to persistent AKI 2

Obstructed Outflow of Urine

• Obstruction can occur at any level of the urinary collecting system, from the renal tubules to the urethral meatus 5, 6
• Common causes include prostatic hypertrophy in older males, nephrolithiasis, tumors, and strictures 4

Risk Factors and Prevention Strategies

• The risk of AKI increases significantly when patients receive multiple nephrotoxic medications simultaneously 2
• Escalating the burden of nephrotoxic medications from two to three more than doubles the risk of developing AKI 2
• Patients should receive potentially nephrotoxic medications only when necessary and for the shortest duration possible 5
• Regular monitoring of kidney function is essential in patients exposed to nephrotoxic agents 5

Management Considerations

• In all phases of AKI, selection of less nephrotoxic alternatives and/or avoidance of nephrotoxins should be the goal 2
• Potentially nephrotoxic agents should not be withheld in life-threatening conditions despite concern for AKI 5

Omeprazole-Associated Acute Kidney Injury

Introduction to Omeprazole-Associated AKI

• The National Kidney Foundation recommends that omeprazole be discontinued immediately if acute kidney injury (AKI) develops, as this drug-induced injury is typically reversible with cessation and potentially corticosteroid therapy, with a reported recovery rate of normal renal function in most cases 7

Prevention and Management

• The American Society of Nephrology suggests using the lowest effective dose of omeprazole for the shortest duration needed, and avoiding its use in patients with known AKI risk factors, such as advanced age, previous AKI episodes, chronic kidney disease, diabetes, proteinuria, or hypertension, with an adjusted risk of 4.35-fold (95% CI 3.14-6.04) for AKI in PPI users versus non-users 7, 8
• The National Institute of Diabetes and Digestive and Kidney Diseases recommends considering less nephrotoxic alternatives, such as H2-receptor antagonists, when appropriate, and implementing regular monitoring of kidney function, particularly in high-risk patients, to reduce the risk of AKI by 53% with each avoided nephrotoxin 7, 8

Epidemiology

• The Centers for Disease Control and Prevention reports that the incidence of AKI is 36.4 per 1000 person-years in PPI users versus 3.54 in non-users, with a significant association between PPI use and increased risk of AKI and chronic kidney disease (CKD), indicating potential for permanent damage 7

Furosemide-Associated Acute Kidney Injury

Mechanisms and Risk Factors

• Acute reduction in renal perfusion can occur even with a single 80 mg intravenous dose in patients with cirrhosis and ascites 9

Clinical Guidelines and Evidence

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that diuretics should not be used to prevent AKI (Grade 1B recommendation) and should not be used to treat AKI, except in the management of volume overload (Grade 2C recommendation) 10
• Higher furosemide doses are associated with worsening renal function, with a multicenter case-control study demonstrating that worsening renal function was associated with a 60 mg greater total daily furosemide dose 11, 12
• In acute heart failure, high-dose furosemide was associated with higher rates of myocardial infarction and intubation 11, 12
• The KDIGO guidelines also state that furosemide does not prevent AKI and may lead to increased mortality based on randomized controlled trials and meta-analyses 10

Appropriate Use of Furosemide

• Furosemide should be used when volume overload is present, as higher furosemide doses had a protective effect on mortality in patients with AKI and positive fluid balance 10
• Furosemide should be used with caution in heart failure with fluid retention, with careful titration essential 11, 12

Evidence‑Based Points on Differential Diagnosis and Management of Cefuroxime‑Induced Acute Interstitial Nephritis

Differential Diagnosis – Renal Vasculitis

• Rapidly progressive glomerulonephritis presenting with active urinary sediment (dysmorphic red blood cells and red‑cell casts) is a hallmark of renal vasculitis in patients with acute kidney injury. 13, 14, 15 – evidence derived from observational kidney‑disease cohorts (Kidney International, 2021).
• Positive anti‑neutrophil cytoplasmic antibody (ANCA) serology (MPO‑ANCA or PR3‑ANCA) or other vasculitis markers strongly supports a diagnosis of renal vasculitis. 13, 14 – based on retrospective analyses (Kidney International, 2021).
• Systemic manifestations that extend beyond an isolated respiratory infection (e.g., skin lesions, neuropathy, pulmonary hemorrhage) are typical for renal vasculitis and help differentiate it from drug‑induced AIN. 13, 15 – observational data (Kidney International, 2021).
• In patients with rheumatoid arthritis receiving only hydroxychloroquine, the baseline risk of vasculitis is not sufficient to make vasculitis the primary explanation for new‑onset AKI. 13 – cohort study findings (Kidney International, 2021).

Differential Diagnosis – Immune‑Complex Glomerulonephritis

• The presence of proteinuria, hematuria, and either nephritic or nephrotic‑type clinical features characterizes immune‑complex glomerulonephritis in the setting of acute kidney injury. 13, 14 – case‑series review (Kidney International, 2021).
• Complement consumption (low C3/C4) and other serologic abnormalities are frequently observed in immune‑complex glomerulonephritis, aiding its distinction from drug‑induced AIN. 13, 14 – observational reports (Kidney International, 2021).

Management – Antibiotic Substitution and Medication Review

• When cefuroxime‑induced AIN is suspected, clinicians should discontinue cefuroxime and switch to an alternative antimicrobial from a different drug class to complete treatment of the underlying infection. 16 – expert consensus/review (Nature Reviews Nephrology, 2017).
• A systematic review of nephrotoxic exposures recommends reviewing all concurrent medications and stopping any non‑essential nephrotoxins to reduce ongoing renal injury. 16 – expert guidance (Nature Reviews Nephrology, 2017).